Company: PETVW
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001493152-25-006783
Chunk: 41

Company: PetVivo Holdings, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
ions such as
osteoarthritis in dogs and horses, in the second quarter of its fiscal year ended March 31, 2022.

The
Company was incorporated in March 2009 under Nevada law under a different name. The Company operates as one segment from its corporate
headquarters in Edina, Minnesota.

CURRENT
BUSINESS OPERATIONS

The
Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage
afflictions of companion animals such as dogs and horses. Most of our technology was developed for human biomedical applications, and
we intend to leverage the investments already expended in their development to commercialize treatments for horses and companion animals
in a capital and time-efficient way.

The
Company’s initial product, Spryng™, and its pipeline products are derived from proprietary biomaterials that simulate a body’s
cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions which incorporate such “tissue building
blocks” as collagen, elastin, and proteoglycans such as heparin. Since these are naturally-occurring in the body, we believe they
have an enhanced biocompatibility with living tissues compared to synthetic biomaterials such as those based upon alpha-hydroxy polymers
(e.g PLA, PLGA, and the like), polyacrylamides, and other “natural” biomaterials that may lack the multiple proteins incorporated
into our biomaterials. These proprietary protein-based biomaterials are similar to the body’s tissue thus allowing integration
and tissue repair in long-term implantation in certain applications.

Our
initial product, Spryng™, is a veterinary medical device designed to help reinforce and/or augment articular cartilage tissue for
the management of lameness and other joint related afflictions, such as osteoarthritis, in horses and companion animals. Spryng™
is an intra-articular injectable product of biocompatible and insoluble particles that are slippery, wet-permeable, durable, and resilient
to enhance the force cushioning function of the synovial fluid and cartilage. The particles mimic natural cartilage in composition, structure,
and hydration. Multiple joints can be treated simultaneously. Our particles are comprised of collagen, elastin, and heparin, similar
components found in natural cartilage. These particles show an effectiveness to reinforce and/or augment the cartilage, which enhances
the functionality of the joint (e.g. provide